| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 7 | 2025 | 271 | 2.720 |
Why?
|
| Mitochondria | 12 | 2025 | 729 | 2.320 |
Why?
|
| src-Family Kinases | 2 | 2025 | 90 | 1.340 |
Why?
|
| Fatty Acids | 8 | 2025 | 351 | 1.110 |
Why?
|
| Cell Line, Tumor | 24 | 2025 | 3503 | 0.940 |
Why?
|
| Biguanides | 1 | 2025 | 12 | 0.910 |
Why?
|
| Breast Neoplasms | 13 | 2024 | 2586 | 0.890 |
Why?
|
| DNA, Mitochondrial | 4 | 2014 | 234 | 0.750 |
Why?
|
| NF-kappa B | 1 | 2024 | 438 | 0.710 |
Why?
|
| Signal Transduction | 6 | 2025 | 4489 | 0.650 |
Why?
|
| Antineoplastic Agents | 4 | 2025 | 1759 | 0.630 |
Why?
|
| CD24 Antigen | 3 | 2024 | 30 | 0.530 |
Why?
|
| Energy Metabolism | 3 | 2021 | 762 | 0.520 |
Why?
|
| Glycolysis | 5 | 2025 | 169 | 0.510 |
Why?
|
| Oxidative Phosphorylation | 6 | 2025 | 126 | 0.490 |
Why?
|
| Neoplasms | 6 | 2025 | 2852 | 0.420 |
Why?
|
| Honey | 2 | 2002 | 5 | 0.380 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2025 | 169 | 0.370 |
Why?
|
| Cell Fusion | 1 | 2012 | 33 | 0.370 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 236 | 0.360 |
Why?
|
| Luminescent Agents | 3 | 2016 | 6 | 0.340 |
Why?
|
| Europium | 3 | 2016 | 6 | 0.340 |
Why?
|
| Animals | 27 | 2025 | 33212 | 0.340 |
Why?
|
| Cell Nucleus | 1 | 2013 | 552 | 0.340 |
Why?
|
| Phosphorylation | 4 | 2024 | 1538 | 0.310 |
Why?
|
| Mice | 16 | 2025 | 17695 | 0.310 |
Why?
|
| Crohn Disease | 2 | 2023 | 290 | 0.300 |
Why?
|
| Cell Proliferation | 7 | 2025 | 2400 | 0.300 |
Why?
|
| Humans | 53 | 2025 | 127501 | 0.300 |
Why?
|
| Wnt1 Protein | 1 | 2009 | 74 | 0.290 |
Why?
|
| Egg White | 1 | 2008 | 10 | 0.290 |
Why?
|
| Mice, Nude | 2 | 2025 | 708 | 0.290 |
Why?
|
| Cytochrome P-450 CYP2D6 | 3 | 2001 | 33 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2025 | 1932 | 0.280 |
Why?
|
| Mutation | 6 | 2025 | 5950 | 0.260 |
Why?
|
| PPAR alpha | 2 | 2024 | 53 | 0.260 |
Why?
|
| Glucose | 4 | 2025 | 839 | 0.260 |
Why?
|
| Estrogens | 2 | 2009 | 424 | 0.250 |
Why?
|
| Heterozygote | 1 | 2009 | 691 | 0.250 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 510 | 0.250 |
Why?
|
| Glutamine | 2 | 2025 | 196 | 0.250 |
Why?
|
| DNA-Binding Proteins | 2 | 2009 | 1892 | 0.250 |
Why?
|
| Muscle, Skeletal | 2 | 2025 | 973 | 0.240 |
Why?
|
| Polymorphism, Genetic | 5 | 2005 | 788 | 0.240 |
Why?
|
| DNA Repair | 3 | 2022 | 549 | 0.240 |
Why?
|
| Nanotubes | 2 | 2016 | 17 | 0.240 |
Why?
|
| Electron Transport Complex I | 2 | 2024 | 32 | 0.240 |
Why?
|
| Food-Drug Interactions | 2 | 2002 | 10 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2025 | 947 | 0.230 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 533 | 0.230 |
Why?
|
| Carcinogenesis | 2 | 2019 | 344 | 0.220 |
Why?
|
| Dasatinib | 1 | 2025 | 48 | 0.220 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2024 | 4 | 0.220 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2025 | 192 | 0.220 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2024 | 8 | 0.220 |
Why?
|
| Transcriptome | 3 | 2025 | 1072 | 0.220 |
Why?
|
| Glutaminase | 1 | 2024 | 17 | 0.220 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2025 | 67 | 0.220 |
Why?
|
| Oncolytic Viruses | 1 | 2025 | 75 | 0.220 |
Why?
|
| Oncolytic Virotherapy | 1 | 2025 | 89 | 0.210 |
Why?
|
| Female | 24 | 2025 | 68765 | 0.210 |
Why?
|
| Ileitis | 1 | 2023 | 10 | 0.210 |
Why?
|
| Adenosine Triphosphate | 4 | 2022 | 266 | 0.210 |
Why?
|
| DNA Damage | 2 | 2017 | 498 | 0.210 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 144 | 0.200 |
Why?
|
| Carcinogens | 2 | 2017 | 128 | 0.200 |
Why?
|
| Metformin | 1 | 2025 | 159 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2016 | 235 | 0.200 |
Why?
|
| Diltiazem | 1 | 2002 | 14 | 0.190 |
Why?
|
| Adipogenesis | 1 | 2023 | 80 | 0.190 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2901 | 0.190 |
Why?
|
| Carbamazepine | 1 | 2002 | 43 | 0.190 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 689 | 0.190 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 627 | 0.180 |
Why?
|
| Life Style | 1 | 2025 | 436 | 0.180 |
Why?
|
| Rothmund-Thomson Syndrome | 1 | 2021 | 48 | 0.180 |
Why?
|
| RecQ Helicases | 1 | 2021 | 62 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 4 | 2008 | 1485 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 727 | 0.180 |
Why?
|
| Stomach Ulcer | 4 | 2001 | 93 | 0.170 |
Why?
|
| Ataxia Telangiectasia | 1 | 2021 | 14 | 0.170 |
Why?
|
| Mutant Proteins | 2 | 2019 | 112 | 0.170 |
Why?
|
| Duodenal Ulcer | 4 | 2001 | 126 | 0.170 |
Why?
|
| Kidney Neoplasms | 2 | 2016 | 438 | 0.170 |
Why?
|
| Hypogonadism | 1 | 2025 | 318 | 0.170 |
Why?
|
| Obesity | 2 | 2025 | 2338 | 0.170 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2021 | 29 | 0.170 |
Why?
|
| Mice, SCID | 3 | 2016 | 570 | 0.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 97 | 0.170 |
Why?
|
| Glioma | 1 | 2025 | 480 | 0.170 |
Why?
|
| Autophagy | 2 | 2016 | 405 | 0.170 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1562 | 0.160 |
Why?
|
| Computational Biology | 1 | 2025 | 835 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 1232 | 0.160 |
Why?
|
| Oxidation-Reduction | 2 | 2023 | 425 | 0.160 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2019 | 30 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 415 | 0.160 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 238 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 192 | 0.160 |
Why?
|
| Reactive Oxygen Species | 3 | 2025 | 493 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 3 | 2021 | 329 | 0.150 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 320 | 0.150 |
Why?
|
| Anticonvulsants | 1 | 2002 | 376 | 0.150 |
Why?
|
| Estrogen Receptor beta | 1 | 2019 | 81 | 0.150 |
Why?
|
| Testosterone | 1 | 2025 | 597 | 0.150 |
Why?
|
| Resistance Training | 1 | 2019 | 26 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 776 | 0.150 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 37 | 0.150 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 227 | 0.150 |
Why?
|
| Osteosarcoma | 1 | 2021 | 261 | 0.150 |
Why?
|
| Antioxidants | 1 | 2021 | 323 | 0.150 |
Why?
|
| India | 5 | 2005 | 229 | 0.150 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 229 | 0.150 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 90 | 0.140 |
Why?
|
| Optical Imaging | 2 | 2016 | 72 | 0.140 |
Why?
|
| Gastric Acid | 4 | 2001 | 50 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 623 | 0.140 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2018 | 24 | 0.140 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2018 | 22 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 393 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 252 | 0.140 |
Why?
|
| Response Elements | 1 | 2018 | 99 | 0.140 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2018 | 51 | 0.140 |
Why?
|
| Models, Biological | 4 | 2025 | 1374 | 0.130 |
Why?
|
| Endoribonucleases | 1 | 2018 | 84 | 0.130 |
Why?
|
| Inflammation | 2 | 2023 | 1435 | 0.130 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2017 | 32 | 0.130 |
Why?
|
| Mutagens | 1 | 2017 | 48 | 0.130 |
Why?
|
| Tobacco Products | 1 | 2017 | 60 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 204 | 0.130 |
Why?
|
| Muscle Proteins | 1 | 2019 | 398 | 0.120 |
Why?
|
| Hexosamines | 1 | 2016 | 18 | 0.120 |
Why?
|
| Nanotechnology | 1 | 2016 | 48 | 0.120 |
Why?
|
| Chloroquine | 1 | 2016 | 30 | 0.120 |
Why?
|
| Cell Survival | 3 | 2013 | 840 | 0.120 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 784 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 2 | 2010 | 424 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 167 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 1235 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 796 | 0.120 |
Why?
|
| Gadolinium | 1 | 2016 | 110 | 0.120 |
Why?
|
| Cell Line | 3 | 2019 | 2566 | 0.120 |
Why?
|
| Molecular Imaging | 2 | 2015 | 60 | 0.120 |
Why?
|
| Prostate | 1 | 2018 | 406 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 394 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 361 | 0.110 |
Why?
|
| Apoptosis | 3 | 2017 | 1823 | 0.110 |
Why?
|
| Graphite | 2 | 2012 | 14 | 0.110 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 90 | 0.110 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 66 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 39 | 0.110 |
Why?
|
| Mixed Function Oxygenases | 1 | 2005 | 36 | 0.110 |
Why?
|
| Tissue Fixation | 1 | 2005 | 36 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2005 | 64 | 0.110 |
Why?
|
| Receptors, Androgen | 1 | 2018 | 403 | 0.110 |
Why?
|
| HeLa Cells | 2 | 2021 | 684 | 0.110 |
Why?
|
| Phosphates | 1 | 2015 | 108 | 0.110 |
Why?
|
| Gene Deletion | 2 | 2010 | 769 | 0.110 |
Why?
|
| DNA | 2 | 2022 | 1422 | 0.110 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 297 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 1206 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 125 | 0.110 |
Why?
|
| Drug Design | 1 | 2015 | 153 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 348 | 0.100 |
Why?
|
| Prognosis | 3 | 2019 | 4803 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2017 | 1032 | 0.100 |
Why?
|
| Hybrid Cells | 1 | 2013 | 78 | 0.100 |
Why?
|
| Exercise | 1 | 2019 | 845 | 0.100 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 85 | 0.100 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 714 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2005 | 415 | 0.100 |
Why?
|
| Yttrium | 1 | 2012 | 5 | 0.100 |
Why?
|
| Paneth Cells | 2 | 2023 | 20 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 416 | 0.100 |
Why?
|
| Heterografts | 1 | 2013 | 190 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 1008 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 123 | 0.090 |
Why?
|
| Half-Life | 2 | 2002 | 151 | 0.090 |
Why?
|
| Smoking | 1 | 2017 | 905 | 0.090 |
Why?
|
| Ethidium | 1 | 2012 | 5 | 0.090 |
Why?
|
| Uridine | 1 | 2012 | 31 | 0.090 |
Why?
|
| Quantum Dots | 1 | 2012 | 15 | 0.090 |
Why?
|
| Metal Nanoparticles | 1 | 2012 | 54 | 0.090 |
Why?
|
| Vasotocin | 2 | 2001 | 2 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2013 | 287 | 0.090 |
Why?
|
| Nanostructures | 1 | 2012 | 58 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2002 | 303 | 0.090 |
Why?
|
| Rats | 6 | 2024 | 3397 | 0.090 |
Why?
|
| Rabbits | 2 | 2002 | 626 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2009 | 231 | 0.090 |
Why?
|
| Phenotype | 5 | 2025 | 4309 | 0.090 |
Why?
|
| Carbon | 1 | 2012 | 88 | 0.090 |
Why?
|
| Oxytocin | 2 | 2001 | 68 | 0.090 |
Why?
|
| Anti-Ulcer Agents | 2 | 2001 | 114 | 0.090 |
Why?
|
| Gene Frequency | 3 | 2005 | 740 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2012 | 599 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 606 | 0.080 |
Why?
|
| Transfection | 1 | 2012 | 948 | 0.080 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2009 | 19 | 0.080 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2009 | 19 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 1395 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2007 | 2754 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3721 | 0.080 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2009 | 51 | 0.080 |
Why?
|
| Male | 13 | 2025 | 62895 | 0.070 |
Why?
|
| Contrast Media | 1 | 2012 | 462 | 0.070 |
Why?
|
| Immunity | 1 | 2009 | 175 | 0.070 |
Why?
|
| Egg Proteins | 1 | 2008 | 29 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 53 | 0.070 |
Why?
|
| Proteoglycans | 1 | 2008 | 80 | 0.070 |
Why?
|
| Risk | 1 | 2010 | 735 | 0.070 |
Why?
|
| Hydroxamic Acids | 1 | 2008 | 57 | 0.070 |
Why?
|
| Laminin | 1 | 2008 | 67 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 203 | 0.070 |
Why?
|
| Nanoparticles | 2 | 2024 | 267 | 0.070 |
Why?
|
| Genomics | 1 | 2016 | 1549 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 79 | 0.070 |
Why?
|
| Metabolomics | 2 | 2024 | 455 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2016 | 2542 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2008 | 271 | 0.070 |
Why?
|
| Genetics, Population | 2 | 2005 | 184 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 317 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2019 | 3720 | 0.070 |
Why?
|
| Collagen | 1 | 2008 | 292 | 0.060 |
Why?
|
| Genotype | 3 | 2005 | 2600 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2008 | 649 | 0.060 |
Why?
|
| Anthracyclines | 2 | 2007 | 43 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 563 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2025 | 90 | 0.060 |
Why?
|
| Hemochromatosis | 1 | 2005 | 38 | 0.060 |
Why?
|
| Luminescent Measurements | 2 | 2016 | 54 | 0.050 |
Why?
|
| Prolactin | 2 | 2001 | 111 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 330 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2016 | 192 | 0.050 |
Why?
|
| Iron | 2 | 2023 | 300 | 0.050 |
Why?
|
| Dextromethorphan | 2 | 2001 | 10 | 0.050 |
Why?
|
| Base Sequence | 3 | 2014 | 2760 | 0.050 |
Why?
|
| Butyrates | 1 | 2023 | 41 | 0.050 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2023 | 9 | 0.050 |
Why?
|
| Adult | 7 | 2021 | 30603 | 0.050 |
Why?
|
| Flavoproteins | 1 | 2023 | 20 | 0.050 |
Why?
|
| Ceramides | 1 | 2023 | 46 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 477 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1382 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 2110 | 0.050 |
Why?
|
| Bone Density | 1 | 2025 | 354 | 0.050 |
Why?
|
| Phosphofructokinase-1 | 1 | 2022 | 6 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2025 | 210 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2021 | 24 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 666 | 0.050 |
Why?
|
| Fasting | 1 | 2023 | 300 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.050 |
Why?
|
| Citric Acid Cycle | 1 | 2022 | 42 | 0.050 |
Why?
|
| Hyperprolactinemia | 1 | 2001 | 23 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 87 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2001 | 77 | 0.040 |
Why?
|
| Tamoxifen | 2 | 2010 | 345 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 537 | 0.040 |
Why?
|
| Enterocytes | 1 | 2021 | 65 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2021 | 162 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2021 | 160 | 0.040 |
Why?
|
| Rats, Wistar | 4 | 2001 | 307 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1601 | 0.040 |
Why?
|
| Epithelium | 1 | 2021 | 340 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2002 | 686 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2021 | 199 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 224 | 0.040 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2019 | 5 | 0.040 |
Why?
|
| DNA Primers | 2 | 2011 | 604 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 210 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 6716 | 0.040 |
Why?
|
| Stomach | 1 | 2001 | 267 | 0.040 |
Why?
|
| Aged | 4 | 2025 | 20512 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2021 | 318 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2019 | 69 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 4987 | 0.040 |
Why?
|
| Drosophila | 1 | 2023 | 769 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 167 | 0.040 |
Why?
|
| Middle Aged | 5 | 2024 | 27886 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2023 | 754 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 151 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2005 | 1509 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 349 | 0.040 |
Why?
|
| Metribolone | 1 | 2018 | 28 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 355 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1310 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 984 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 61 | 0.030 |
Why?
|
| Butanones | 1 | 2017 | 7 | 0.030 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 12 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 24 | 0.030 |
Why?
|
| Nitrosamines | 1 | 2017 | 15 | 0.030 |
Why?
|
| Benzo(a)pyrene | 1 | 2017 | 24 | 0.030 |
Why?
|
| Acetic Acid | 3 | 2001 | 17 | 0.030 |
Why?
|
| Cysteamine | 3 | 2001 | 15 | 0.030 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2007 | 19 | 0.030 |
Why?
|
| Pylorus | 3 | 2001 | 20 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 1237 | 0.030 |
Why?
|
| Azacitidine | 1 | 2017 | 51 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 3588 | 0.030 |
Why?
|
| DNA Adducts | 1 | 2017 | 71 | 0.030 |
Why?
|
| Indomethacin | 3 | 2001 | 81 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2017 | 9 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 978 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 79 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2007 | 132 | 0.030 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2017 | 68 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 261 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 359 | 0.030 |
Why?
|
| Magnets | 1 | 2016 | 19 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 303 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2016 | 40 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 44 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 1774 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 197 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 384 | 0.030 |
Why?
|
| Carboplatin | 1 | 2016 | 77 | 0.030 |
Why?
|
| Superoxides | 1 | 2016 | 129 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 662 | 0.030 |
Why?
|
| Androgens | 1 | 2018 | 269 | 0.030 |
Why?
|
| Haplotypes | 1 | 2007 | 525 | 0.030 |
Why?
|
| Liver | 1 | 2023 | 1765 | 0.030 |
Why?
|
| Weight Loss | 1 | 2019 | 503 | 0.030 |
Why?
|
| Taq Polymerase | 1 | 2005 | 7 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 231 | 0.030 |
Why?
|
| Methotrexate | 1 | 2007 | 317 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2018 | 396 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2005 | 5 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 900 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2005 | 39 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2005 | 25 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2005 | 36 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 138 | 0.030 |
Why?
|
| Kidney | 1 | 2001 | 1283 | 0.030 |
Why?
|
| Breast Diseases | 1 | 2005 | 37 | 0.030 |
Why?
|
| Metabolome | 1 | 2017 | 316 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2014 | 81 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 121 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 283 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1871 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 396 | 0.030 |
Why?
|
| Telomerase | 1 | 2014 | 153 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2001 | 1200 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4448 | 0.020 |
Why?
|
| Chromatin | 1 | 2016 | 472 | 0.020 |
Why?
|
| Histones | 1 | 2016 | 503 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 852 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2012 | 102 | 0.020 |
Why?
|
| Oxides | 1 | 2012 | 16 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 130 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2016 | 873 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 123 | 0.020 |
Why?
|
| Surface Properties | 1 | 2012 | 81 | 0.020 |
Why?
|
| Fluorescence | 1 | 2012 | 97 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2012 | 106 | 0.020 |
Why?
|
| Particle Size | 1 | 2012 | 133 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 425 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 643 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1601 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 1235 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2005 | 1500 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 656 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2010 | 20 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2010 | 39 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 82 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 566 | 0.020 |
Why?
|
| Alleles | 1 | 2005 | 1610 | 0.020 |
Why?
|
| Ethanol | 2 | 2001 | 159 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2010 | 213 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2009 | 37 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1064 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 292 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2016 | 871 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1005 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 412 | 0.020 |
Why?
|
| Acute Disease | 2 | 2001 | 1142 | 0.020 |
Why?
|
| Estradiol | 1 | 2010 | 477 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3596 | 0.020 |
Why?
|
| RNA Interference | 1 | 2009 | 494 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 3052 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 1282 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 1187 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 6172 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2543 | 0.010 |
Why?
|
| Germany | 1 | 2005 | 50 | 0.010 |
Why?
|
| Menopause | 1 | 2005 | 84 | 0.010 |
Why?
|
| Child | 1 | 2023 | 25302 | 0.010 |
Why?
|
| Ranitidine | 1 | 2001 | 30 | 0.010 |
Why?
|
| Adolescent | 1 | 2000 | 20156 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 2001 | 157 | 0.010 |
Why?
|
| Gastric Acidity Determination | 1 | 2001 | 24 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2001 | 55 | 0.010 |
Why?
|
| Histamine | 1 | 2001 | 50 | 0.010 |
Why?
|
| Receptors, Oxytocin | 1 | 2001 | 21 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4513 | 0.010 |
Why?
|
| Ligation | 1 | 2001 | 136 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2001 | 129 | 0.010 |
Why?
|
| Duodenum | 1 | 2001 | 110 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1791 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 642 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 12583 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2007 | 17080 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2001 | 487 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 3332 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 3261 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 10636 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 7426 | 0.000 |
Why?
|